Key facts
- This page summarizes Dennis Podlesak's Form 4 filing for Syndax Pharmaceuticals Inc (SNDX).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 30 Oct 2026, 19:09.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Options Exercise
Sale
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Options Exercise
Additional SEC filing notes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Footnote F1
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person solely covering equity grants with expiration dates prior to Octobre 31, 2026. Following the sales reported in this Form 4, the Reporting Person has a total of 127,000 options to purchase shares of common stock that are vested and immediately exercisable and no unvested options to purchase shares of common stock.
Footnote F2
The sale prices ranged from $14.00 to $14.59.
Footnote F3
This option is fully vested.